Neurological complications of anti-PD-1 antibodies: shall we be more concerned?

Kyrillus S. Shohdy, Omar Abdel-Rahman


Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target receptors expressed on surface of T-lymphocytes and tumor cells, those receptors such as programmed death receptor-1 (PD-1), and the programmed death-ligand 1 (PD-L1) mediate an immunosuppressive state characterized by T cell anergy that enables institution of tumorigenesis.